Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 9 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,565 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 6,160 | $36.72 | $226,195.20 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.45 to $37.00 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,725 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 6,160 | $36.91 | $227,365.60 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $37.50 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-006377 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC |
Hinson Andrew GDirector
|
SaleCommon Stock | 1,300 | $37.32 | $48,516.00 |
DisclosureSEC source: 0001437749-21-006376 · rdgdoc.xml · nonDerivative · entry 2 Hinson Andrew G · CIK 0001389410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,461 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:01 UTC |
Hinson Andrew GDirector
|
SaleCommon Stock | 1,200 | $37.32 | $44,784.00 |
DisclosureSEC source: 0001437749-21-006376 · rdgdoc.xml · nonDerivative · entry 1 Hinson Andrew G · CIK 0001389410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,761 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:43 UTC |
Rice MichaelDirector · President & CEO
|
SaleCommon Stock | 861 | $39.57 | $34,069.77 |
DisclosureSEC source: 0001437749-21-004768 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,331 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:42 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
SaleCommon Stock | 403 | $39.57 | $15,946.71 |
DisclosureSEC source: 0001437749-21-004766 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,997 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:42 UTC |
Foster Karen A.Chief Quality Officer
|
SaleCommon Stock | 284 | $39.57 | $11,237.88 |
DisclosureSEC source: 0001437749-21-004767 · rdgdoc.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,973 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:00 UTC |
Foster Karen A.Chief Quality Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,334 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-003996 · rdgdoc.xml · derivative · entry 3 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,989 Underlying: Common Stock · 16,334 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 163,323 shares of common stock which vested in two equal installments on March 8, 2018 and March 8, 2019. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:00 UTC |
Foster Karen A.Chief Quality Officer
|
SaleCommon Stock | 16,334 | $39.66 | $647,806.44 |
DisclosureSEC source: 0001437749-21-003996 · rdgdoc.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.45 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:00 UTC |
Foster Karen A.Chief Quality Officer
|
Exercise / conversionCommon Stock | 16,334 | $1.64 | $26,787.76 |
DisclosureSEC source: 0001437749-21-003996 · rdgdoc.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
SaleCommon Stock | 3,344 | $40.76 | $136,301.44 |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · nonDerivative · entry 5 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,257 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
SaleCommon Stock | 4,728 | $40.76 | $192,713.28 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,400 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
SaleCommon Stock | 10,107 | $40.76 | $411,961.32 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,192 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 1,876 | $40.76 | $76,465.76 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,870 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC |
DE GREEF RODERICKCFO & COO
|
SaleCommon Stock | 4,509 | $40.76 | $183,786.84 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,132 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
SaleCommon Stock | 3,353 | $40.67 | $136,366.51 |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · nonDerivative · entry 4 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,601 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
SaleCommon Stock | 4,741 | $40.67 | $192,816.47 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,128 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
SaleCommon Stock | 10,132 | $40.67 | $412,068.44 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,299 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 1,882 | $40.67 | $76,540.94 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,746 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
DE GREEF RODERICKCFO & COO
|
SaleCommon Stock | 4,520 | $40.67 | $183,828.40 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,641 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
SaleCommon Stock | 3,281 | $41.55 | $136,325.55 |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · nonDerivative · entry 3 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,954 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
SaleCommon Stock | 4,640 | $41.55 | $192,792.00 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,869 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
SaleCommon Stock | 9,917 | $41.55 | $412,051.35 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,431 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 1,842 | $41.55 | $76,535.10 |
DisclosureSEC source: 0001437749-21-003513 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,628 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
DE GREEF RODERICKCFO & COO
|
SaleCommon Stock | 4,424 | $41.55 | $183,817.20 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,161 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:00 UTC |
Hinson Andrew GDirector
|
SaleCommon Stock | 2,500 | $45.67 | $114,175.00 |
DisclosureSEC source: 0001437749-21-003179 · rdgdoc.xml · nonDerivative · entry 1 Hinson Andrew G · CIK 0001389410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,961 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,160 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · derivative · entry 6 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,885 Underlying: Common Stock · 6,160 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,164 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · derivative · entry 5 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,045 Underlying: Common Stock · 6,164 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 6,160 | $44.25 | $272,580.00 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 4 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.73 to $44.8 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionCommon Stock | 6,160 | $1.64 | $10,102.40 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 3 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
SaleCommon Stock | 6,164 | $44.70 | $275,530.80 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.68 to $45.5 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:04 UTC |
Berard ToddChief Marketing Officer
|
Exercise / conversionCommon Stock | 6,164 | $1.64 | $10,108.96 |
DisclosureSEC source: 0001437749-21-003340 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Mar 6, 2021 01:01 UTC Amendment |
Schulz MarcusChief Revenue Officer
|
SaleCommon Stock | 2,000 | $41.01 | $82,020.00 |
DisclosureSEC source: 0001437749-21-005202 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,107 F1 · security: This Form 4/A is being filed to amend the Form 4 originally filed by the reporting person on February 16, 2021 solely to correct the transaction date in Column 2 on Table I. No other changes have been made to the original Form 4. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
GrantRestricted Stock Award · Derivative | 4,157 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · derivative · entry 6 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,157 Underlying: Common Stock · 4,157 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
Exercise / conversionCommon Stock | 23,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · nonDerivative · entry 2 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:02 UTC |
Foster Karen A.Chief Quality Officer
|
GrantCommon Stock | 4,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003518 · rdgdoc.xml · nonDerivative · entry 1 Foster Karen A. · CIK 0001683151 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,899 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
GrantRestricted Stock Award · Derivative | 4,891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,891 Underlying: Common Stock · 4,891 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
Exercise / conversionCommon Stock | 33,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Mathew Aby J.Exec VP & Chief Scientific Off
|
GrantCommon Stock | 4,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,313 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Aebersold SarahVP, Global Human Resources
|
GrantRestricted Stock Award · Derivative | 2,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003516 · rdgdoc.xml · derivative · entry 2 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,795 Underlying: Common Stock · 2,795 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Aebersold SarahVP, Global Human Resources
|
GrantCommon Stock | 2,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003516 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,899 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Schulz MarcusChief Revenue Officer
|
GrantRestricted Stock Award · Derivative | 2,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003515 · rdgdoc.xml · derivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,912 Underlying: Common Stock · 2,912 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC |
Schulz MarcusChief Revenue Officer
|
GrantCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003515 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,019 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
GrantRestricted Stock Award · Derivative | 7,511 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 7,511 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
Exercise / conversionCommon Stock | 70,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC |
Rice MichaelDirector · President & CEO
|
GrantCommon Stock | 7,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,354 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.